Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children

Conditions

• Allergy
• Eczema
• Infections
• Respiratory Tract Infections

Eligibility Criteria

Sex

ALL

Age

6 Months - 6 Months

Healthy Volunteers

Accepted

Interventions

• Measles-Mumps-Rubella vaccine (MMR) — BIOLOGICAL
  0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh

Study Details

The goal of this clinical trial is to evaluate the off-target/non-specific effects of the measles-mumps-rubella (MMR) vaccine in children.

Key Dates

First listed

Mar 7, 2023

Start date

Mar 17, 2023

Status verified

May 2024

Primary completion

Apr 30, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

500 participants (estimated)

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

PREVENTION

Arms

• Active Comparator: C.C. : Both MMR doses given on current schedule (9 months and 12 months)
  Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at: * 9 months (= current Swiss schedule) * 12 months, concomitant with other vaccines (= current Swiss schedule)
• Experimental: M.C. : 1st MMR on modified schedule (6 months) and 2nd MMR on current schedule (12 months)
  Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at: * 6 months (= modified schedule) * 12 months, concomitant with other vaccines (= current Swiss schedule)
• Experimental: C. M. : 1st MMR on current schedule (9 months) and 2nd MMR on modified schedule (13 months)
  Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at: * 9 months (= current Swiss schedule) * 13 months, distant from other vaccines (= modified schedule)
• Experimental: M.M. : Both MMR doses given on modified schedule (6 months and 13 months)
  Measles-mumps-rubella (MMR) vaccine 0.5 ml injected intramuscularly, at: * 6 months (= modified schedule) * 13 months, distant from other vaccines (= modified schedule)

Primary Outcome Measure

Incidence of respiratory infection within the 3 months following randomisation [ Time Frame: Measured over the 3 months following randomisation ]

Central Contacts

• Laure F Pittet, MD-PhD
  +41 22 372 33 11
  [email protected]

Find similar trials

Related Studies

• Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Studies of Skin Microbes in Healthy People and in People With Skin Conditions
  Recruiting · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland
• A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
  PHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland